CHINA BIOLOGIC PRODS HLDGS I's ticker is CBPO and the CUSIP is G21515104. A total of 89 filers reported holding CHINA BIOLOGIC PRODS HLDGS I in Q2 2018. The put-call ratio across all filers is 1.05 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $7,294,000 | -6.1% | 61,603 | -6.3% | 0.00% | 0.0% |
| Q4 2020 | $7,766,000 | -4.0% | 65,756 | -9.6% | 0.00% | -25.0% |
| Q3 2020 | $8,088,000 | +11.9% | 72,771 | +2.9% | 0.00% | +33.3% |
| Q2 2020 | $7,228,000 | -3.3% | 70,739 | +2.1% | 0.00% | -25.0% |
| Q1 2020 | $7,474,000 | +2.8% | 69,254 | +10.9% | 0.00% | +33.3% |
| Q4 2019 | $7,269,000 | +4.4% | 62,459 | +2.7% | 0.00% | -25.0% |
| Q3 2019 | $6,965,000 | +2995.6% | 60,844 | +2481.4% | 0.00% | – |
| Q2 2019 | $225,000 | +4.7% | 2,357 | 0.0% | 0.00% | – |
| Q1 2019 | $215,000 | +20.1% | 2,357 | 0.0% | 0.00% | – |
| Q4 2018 | $179,000 | -5.3% | 2,357 | 0.0% | 0.00% | – |
| Q3 2018 | $189,000 | +1.1% | 2,357 | +25.2% | 0.00% | – |
| Q2 2018 | $187,000 | -22.1% | 1,882 | -36.5% | 0.00% | – |
| Q1 2018 | $240,000 | +2.6% | 2,966 | 0.0% | 0.00% | – |
| Q4 2017 | $234,000 | -14.6% | 2,966 | 0.0% | 0.00% | – |
| Q3 2017 | $274,000 | – | 2,966 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kite Lake Capital Management (UK) LLP | 207,382 | $24,135,000 | 76.46% |
| Maso Capital Partners Ltd | 539,597 | $62,798,000 | 20.20% |
| York Capital Management Global Advisors, LLC | 1,102,163 | $128,270,000 | 7.40% |
| HHLR ADVISORS, LTD. | 2,751,200 | $320,185,000 | 3.99% |
| Dalton Investments, Inc. | 15,551 | $1,810,000 | 1.14% |
| Athos Capital Ltd | 8,290 | $965,000 | 0.96% |
| Myriad Asset Management Ltd. | 67,019 | $7,799,000 | 0.94% |
| Temasek Holdings (Private) Ltd | 990,000 | $115,216,000 | 0.75% |
| OXFORD ASSET MANAGEMENT LLP | 211,646 | $24,631,000 | 0.68% |
| AGF Investments America Inc. | 12,230 | $1,423,000 | 0.47% |